Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Assembly Biosciences (ASMB)

4.48   -0.15 (-3.24%) 03-07 04:43
Open: 4.64 Pre. Close: 4.63
High: 4.66 Low: 4.305
Volume: 2,599,252 Market Cap: 171M
Assembly Biosciences, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome. It is involved in the development of core inhibitors that inhibit the functional activities of HBV core protein at various points in the viral lifecycle. The company's microbiome program consists of an integrated platform that includes the disease-targeted strain isolation, identification, characterization, and selection process for strain purification and growth under current good manufacturing practice conditions; and a licensed patented delivery system, GEMICEL, which allows for targeted oral delivery of live biologic and conventional therapies to the lower gastrointestinal tract. Its product candidates include ABI-H0731 that is in Phase 2a clinical trials for the treatment of HBV; ABI-H2158, which is in Phase 1a/1b dose-ranging clinical study in the HBV-cure program; and ABI-H3733 that is in preclinical studies for the treatment of HBV. In addition, the company engages in the development of product candidates for various disease indications, such as Crohn's disease, irritable bowel syndrome, immune-mediated and metabolic disorders, and oncology by using its microbiome platform. It has a collaboration agreement with Allergan Pharmaceuticals International Limited for the development and commercialization of various microbiome gastrointestinal programs. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was founded in 2005 and is headquartered in South San Francisco, California.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 4.69 - 4.735 4.735 - 4.763
Low: 4.209 - 4.265 4.265 - 4.299
Close: 4.414 - 4.508 4.508 - 4.564

Technical analysis

as of: 2021-03-05 5:05:08 PM
Overall:       
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 6.99     One year: 8.20
Support: Support1: 4.30    Support2: 3.58
Resistance: Resistance1: 5.98    Resistance2: 7.02
Pivot: 5.44
Moving Average: MA(5): 4.81     MA(20): 5.69
MA(100): 7.63     MA(250): 14.68
MACD: MACD(12,26): -0.37     Signal(9): -0.24
Stochastic oscillator: %K(14,3): 4.54     %D(3): 2.69
RSI: RSI(14): 21.94
52-week: High: 27.84  Low: 4.30  Change(%): -74.4
Average Vol(K): 3-Month: 127645  10-Days: 213207

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and BEARISH in mid-long term.
ASMB has closed above bottom band by 5.7%. Bollinger Bands are 33% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Fri, 05 Mar 2021
Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance

Thu, 04 Mar 2021
Truist Securiti Comments on Assembly Biosciences, Inc.'s FY2021 Earnings (NASDAQ:ASMB) - MarketBeat

Sun, 28 Feb 2021
Assembly Biosciences, Inc. (ASMB) CEO on Hepatitis B Program Update Call Transcript - Seeking Alpha

Sun, 28 Feb 2021
Assembly Biosciences (ASMB) Receives a Buy from Robert W. Baird - Analyst Ratings

Fri, 26 Feb 2021
Is Assembly Biosciences Inc (ASMB) Stock Worth a Buy Friday? - InvestorsObserver

Thu, 25 Feb 2021
Assembly Biosciences: 4Q Earnings Snapshot - San Francisco Chronicle

Financial Analysis

Growth
Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Price to Book Value: Outperform Discounted cash flow: Outperform
Return on Assets: Underperform Price to Earnings: Underperform
Return on Equity: Underperform Debt to Equity: Neutral
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 33
Shares Float (M) 25
% Held by Insiders 4.65
% Held by Institutions 94.26
Shares Short (K) 2,600
Shares Short P. Month (K) 2,990

Stock Financials

EPS -1.490
EPS Est This Year
EPS Est Next Year
Book Value (p.s.) 8.220
Profit Margin -60.14
Operating Margin -62.92
Return on Assets (ttm) -12.3
Return on Equity (ttm) -23.3
Qtrly Rev. Growth 718.0
Gross Profit (p.s.) -2.114
Sales Per Share 2.508
EBITDA (p.s.) -1.563
Qtrly Earnings Growth
Operating Cash Flow (M) -58
Levered Free Cash Flow (M) -13

Stock Valuations

PE Ratio -3.01
PEG Ratio
Price to Book value 0.55
Price to Sales 1.78
Price to Cash Flow -2.54

Stock Dividends

Dividend
Forward Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
android_stock_chart
Stock Chart
stoxline_lite
Stoxline Lite
stoxline_pro
Stoxline Pro
Option_Calculator
Option Calculator
(c) 2006-2020 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.